Featured Research

from universities, journals, and other organizations

Protein lost in tumors blocks normal cells from being reprogrammed into stem cells

Date:
March 7, 2013
Source:
The Mount Sinai Hospital / Mount Sinai School of Medicine
Summary:
Researchers have discovered that a particular protein prevents normal cells from being reprogrammed into cells that resemble stem cells, providing new insight into how they may lose their plasticity during normal development.

Researchers from the Icahn School of Medicine at Mount Sinai have discovered that a particular protein prevents normal cells from being reprogrammed into cells that resemble stem cells, providing new insight into how they may lose their plasticity during normal development. This finding has broad-reaching implications for how cells change during both normal and disease development.

The data are published this week in Nature Communications.

In a previous study, Emily Bernstein, PhD, and her team at Mount Sinai studied the natural progression of melanoma using mouse and human cells, as well as patient samples, and found that the loss of a specific histone variant called macroH2A, which is a protein that helps package DNA, was directly related to the growth and metastasis of melanoma. In the current study, her team wanted to find out how this molecule might act as a barrier to cellular reprogramming. The importance of cellular reprogramming has been recently highlighted by the winners of the Nobel Prize of Medicine (2012), and explores the capacity of reversing adult cells to an early stage of development, the so called embryonic stem cell.

Working with researchers at the University of Pennsylvania, Dr. Bernstein evaluated mice that were genetically engineered to lack macroH2A in comparison to control or "wild-type" mice. They used skin cells from these mice and attempted to reprogram the cells in petri dishes into pluripotent cells. They found that the cells derived from mice without macroH2A were much more plastic, meaning they were more easily reprogrammed into stem-like cells, compared to the wild-type mice. This indicates that macroH2A may block cellular reprogramming by silencing genes required for plasticity.

"This is the first evidence of the involvement of a histone variant protein as an epigenetic barrier to induced pluripotency (iPS) reprogramming," said Dr. Bernstein, who is an Assistant Professor of Oncological Sciences and Dermatology at the Graduate School of Biomedical Sciences at Mount Sinai, and corresponding author of the study. "These findings help us to understand the progression of different cancers and how macroH2A might be acting as a barrier to tumor development."

Next, Dr. Bernstein and her team plan to create cancer cells in a petri dish by manipulating healthy cells with genetic mutations often associated with cancer, coupled to removal of macroH2A to examine whether the cells are capable of forming tumors.

This study was supported by funding from a New York State Stem Cell Science Award (C024285) and a National Institutes of Health Grant (R01CA154683).


Story Source:

The above story is based on materials provided by The Mount Sinai Hospital / Mount Sinai School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Alexandre Gaspar-Maia, Zulekha A. Qadeer, Dan Hasson, Kajan Ratnakumar, N. Adrian Leu, Gary Leroy, Shichong Liu, Carl Costanzi, David Valle-Garcia, Christoph Schaniel, Ihor Lemischka, Benjamin Garcia, John R. Pehrson, Emily Bernstein. MacroH2A histone variants act as a barrier upon reprogramming towards pluripotency. Nature Communications, 2013; 4: 1565 DOI: 10.1038/ncomms2582

Cite This Page:

The Mount Sinai Hospital / Mount Sinai School of Medicine. "Protein lost in tumors blocks normal cells from being reprogrammed into stem cells." ScienceDaily. ScienceDaily, 7 March 2013. <www.sciencedaily.com/releases/2013/03/130307124808.htm>.
The Mount Sinai Hospital / Mount Sinai School of Medicine. (2013, March 7). Protein lost in tumors blocks normal cells from being reprogrammed into stem cells. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/03/130307124808.htm
The Mount Sinai Hospital / Mount Sinai School of Medicine. "Protein lost in tumors blocks normal cells from being reprogrammed into stem cells." ScienceDaily. www.sciencedaily.com/releases/2013/03/130307124808.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins